Monoclonal antibody form and function: Manufacturing the right antibodies for treating drug abuse

Drug Addiction: From Basic Research to Therapy

Volumn , Issue , 2008, Pages 87-100

  Peterson, Eric ^a   Owens, S Michael ^a   Henry, Ralph L ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS   (United States)

Author keywords

antibody production; antibody therapy

Indexed keywords

EID: 84873073357     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-76678-2_5     Document Type: Chapter

References (32)

1. Pentel P, Malin D. A vaccine for nicotine dependence: Targeting the drug rather than the brain. Respiration (Herrlisheim). 2002;69:193-197.
2. Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR. Vaccination against nicotine during continued nicotine administration in rats: Immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol. 2000;22:809-819.
3. McClurkan MB, Valentine JL, Arnold L, Owens SM. Disposition of a monoclonal antiphencyclidine Fab fragment of immunoglobulin G in rats. J Pharmacol Exp Ther. 1993;266:1439-1445.
4. Valentine JL, Mayersohn M, Wessinger WD, Arnold LW, Owens SM. Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats. J Pharmacol Exp Ther. 1996;278:709-716.
5. Byrnes-Blake KA, Laurenzana EM, Carroll FI, et al. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur J Pharmacol. 2003;461:119-128.
6. McMillan DE, Hardwick WC, Li M, Owens SM. Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-Affinity monoclonal anti-methamphetamine antibody. Behav Pharmacol. 2002;13:465-473.
7. Roskos LK, Davis CG, Schwab GM. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev Res. 2004;61:108-120.
8. Brambell FW, Hemmings WA, Morris IG. A theoretical model of gamma-globulin catabolism. Nature. 1964;203:1352-1354.
9. Junghans RP. Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res. 1997;16:29-57.
10. Ghetie V, Ward ES. Transcytosis and catabolism of antibody. Immunol Res. 2002;25:97-113.
11. Trang J. Pharmacokinetics and metabolism of therapeutic and diagnostic antibodies. In: Ferraiolo B, Mohler M, Gloff C, eds. Protein Pharmacokinetics and Metabolism. New York, NY: Plenum Press; 1992:223-270.
12. Weiner LM. Monoclonal antibody therapy of cancer. Semin Oncol. 1999;26:43-51.
13. Stein KE. Immunogenicity: Concepts/issues/concerns. Dev Biol (Basel). 2002;109:15-23.
14. Kuus-Reichel K, Grauer LS, Karavodin LM, Knott C, Krusemeier M, Kay NE. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin Diagn Lab Immunol. 1994;1:365-372.
15. King DJ, Byron OD, Mountain A, et al. Expression, purification and characterization of B72.3 Fv fragments. Biochem J. 1993;290:723-729.
16. Kadokura H, Katzen F, Beckwith J. Protein disulfide bond formation in prokaryotes. Annu Rev Biochem. 2003;72:111-135. DOI: 10.1146/annurev.biochem.72. 121801.161459.
17. Simmons LC, Reilly D, Klimowski L, et al. Expression of full-length immunoglobulins in Escherichia coli: Rapid and efficient production of aglycosylated antibodies. J Immunol Methods. 2002;263:133-147.
18. Venturi M, Seifert C, Hunte C. High level production of functional antibody Fab fragments in an oxidizing bacterial cytoplasm. J Mol Biol. 2002;315:1-8.
19. Cereghino GP, Cereghino JL, Ilgen C, Cregg JM. Production of recombinant proteins in fermenter cultures of the yeast Pichia pastoris. Curr Opin Biotechnol. 2002;13:329-332.
20. Peterson EC, Farrance C, Henry R, Owens SM. Engineering of a single chain antibody for treatment of methamphetamine abuse. 2004 Experimental Biology meeting abstracts [on CD-ROM]. FASEB J. 2004;18.
21. Damasceno LM, Pla I, Chang HJ, et al. An optimized fermentation process for high-level production of a single-chain Fv antibody fragment in Pichia pastoris. Protein Expr Purif. 2004;37:18-26.
22. Joosten V, Lokman C, Van Den Hondel CA, Punt PJ. The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. Microb Cell Fact. 2003;2:1.
23. Murasugi A, Asami Y, Mera-Kikuchi Y. Production of recombinant human bile salt-stimulated lipase in Pichia pastoris. Protein Expr Purif. 2001;23:282-288.
24. Ma JK, Drake PM, Christou P. The production of recombinant pharmaceutical proteins in plants. Nat Rev Genet. 2003;4:794-805.
25. Gleba Y, Klimyuk V, Marillonnet S. Magnifection-A new platform for expressing recombinant vaccines in plants. Vaccine. 2005;23:2042-2048.
26. Gleba Y, Marillonnet S, Klimyuk V. Engineering viral expression vectors for plants: The 'full virus' and the 'deconstructed virus' strategies. Curr Opin Plant Biol. 2004;7:182-188.
27. Marillonnet S, Thoeringer C, Kandzia R, Klimyuk V, Gleba Y. Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants. Nat Biotechnol. 2005;23:718-723.
28. Santi L, Giritch A, Roy CJ, et al. Protection conferred by recombinant Yersinia pestis antigens produced by a rapid and highly scalable plant expression system. Proc Natl Acad Sci USA. 2006;103:861-866.
29. Gils M, Kandzia R, Marillonnet S, Klimyuk V, Gleba Y. High-yield production of authentic human growth hormone using a plant virus-based expression system. Plant Biotechnol J. 2005;3:613-620.
30. Sharp JM, Doran PM. Characterization of monoclonal antibody fragments produced by plant cells. Biotechnol Bioeng. 2001;73:338-346.
31. Derouazi M, Girard P, Van Tilborgh F, et al. Serum-free large-scale transient transfection of CHO cells. Biotechnol Bioeng. 2004;87:537-545.
32. Baldi L, Muller N, Picasso S, et al. Transient gene expression in suspension HEK-293 cells: Application to large-scale protein production. Biotechnol Prog. 2005;21:148-153.